[go: up one dir, main page]

BRPI0911659B8 - composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo - Google Patents

composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo

Info

Publication number
BRPI0911659B8
BRPI0911659B8 BRPI0911659A BRPI0911659A BRPI0911659B8 BR PI0911659 B8 BRPI0911659 B8 BR PI0911659B8 BR PI0911659 A BRPI0911659 A BR PI0911659A BR PI0911659 A BRPI0911659 A BR PI0911659A BR PI0911659 B8 BRPI0911659 B8 BR PI0911659B8
Authority
BR
Brazil
Prior art keywords
phenylpyrazolo
same
pharmaceutical composition
thiazole compound
cycloalkyl
Prior art date
Application number
BRPI0911659A
Other languages
English (en)
Inventor
Inomata Akira
Shibata Hisashi
Shikata Kodo
Shin Kogyoku
Takeda Kunitoshi
Hashizume Minako
Terauchi Taro
Takahashi Yoshinori
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BRPI0911659A2 publication Critical patent/BRPI0911659A2/pt
Publication of BRPI0911659B1 publication Critical patent/BRPI0911659B1/pt
Publication of BRPI0911659B8 publication Critical patent/BRPI0911659B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto 3-fenilpirazolo[5,1-b]tlazol. a presente invenção refere-se a um composto representado peia seguinte fórmula (i), ou um sal do mesmo exibe excelente antagonismo de receptor de crf, e atividade farmacológica suficiente, propriedades farmacocinéticas e de segurança como um fármaco. m que r1 representa a fórmula -a11 -a12; r2 representa tetra-hidrofurilmetila, tetra-hidropiranilmetila ou tetra-hidropiranila; a11 representa uma iigação simples, metileno ou 1,2-etileno; a12 representa c1-6 alquila, c3-6 cicloalqui- 'la ou c3-6 cicloalquila tendo metila; r3 representa metóxi, ciano, ciclobutilo- ximetila, metoximetila ou etoximetila; e r4 representa metóxi ou cloro.
BRPI0911659A 2008-04-15 2009-04-09 composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo BRPI0911659B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4508408P 2008-04-15 2008-04-15
JP2008-106080 2008-04-15
JP2008106080 2008-04-15
US61/045,084 2008-04-15
PCT/JP2009/057270 WO2009128383A1 (ja) 2008-04-15 2009-04-09 ３－フェニルピラゾロ［５，１－ｂ］チアゾール化合物

Publications (3)

Publication Number Publication Date
BRPI0911659A2 BRPI0911659A2 (pt) 2015-10-13
BRPI0911659B1 BRPI0911659B1 (pt) 2020-08-25
BRPI0911659B8 true BRPI0911659B8 (pt) 2021-05-25

Family

ID=41164535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911659A BRPI0911659B8 (pt) 2008-04-15 2009-04-09 composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo

Country Status (28)

Country Link
US (1) US8431603B2 (pt)
EP (1) EP2266990B1 (pt)
JP (1) JP4654325B2 (pt)
KR (1) KR101601994B1 (pt)
CN (1) CN102007133B (pt)
AR (1) AR071655A1 (pt)
AU (1) AU2009237050B2 (pt)
BR (1) BRPI0911659B8 (pt)
CA (1) CA2721670C (pt)
CL (1) CL2009000896A1 (pt)
CY (1) CY1113484T1 (pt)
DK (1) DK2266990T3 (pt)
ES (1) ES2396126T3 (pt)
HR (1) HRP20121021T1 (pt)
IL (1) IL208393A (pt)
MX (1) MX2010011089A (pt)
MY (1) MY152687A (pt)
NZ (1) NZ588376A (pt)
PE (1) PE20091890A1 (pt)
PL (1) PL2266990T3 (pt)
PT (1) PT2266990E (pt)
RS (1) RS52561B (pt)
RU (1) RU2482120C2 (pt)
SI (1) SI2266990T1 (pt)
TW (1) TW201004964A (pt)
UA (1) UA101836C2 (pt)
WO (1) WO2009128383A1 (pt)
ZA (1) ZA201006764B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52561B (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. COMPOUND 3-PHENYLPYRAZOLO [5,1-B] THIAZOL
WO2011043387A1 (ja) 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CN102020587A (zh) * 2010-11-25 2011-04-20 大连凯飞精细化工有限公司 2-甲氧基-4-氰基苯甲醛的合成方法
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224974A (en) 1880-02-24 wheeler
JPS5320360B2 (pt) 1973-05-30 1978-06-26
JPS51141896A (en) * 1975-05-31 1976-12-07 Sankyo Co Ltd Process for preparing fused ring triazoropyrimidine derivatives
EP0068378B1 (en) 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4596872A (en) * 1985-06-05 1986-06-24 Schering A.G. Imidazo[1,2-a]pyridines, and process for their preparation
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5190862A (en) * 1987-04-01 1993-03-02 Boehringer Mannheim Gmbh Chromogenic compounds and the use thereof as enzyme substrates
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
FR2619818B1 (fr) * 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5055479A (en) 1988-06-16 1991-10-08 Sankyo Company, Limited Method of treating cachexia
JPH03506033A (ja) 1988-07-19 1991-12-26 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換フエニルトリアゾロピリミジン除草剤
US5127936A (en) * 1988-07-19 1992-07-07 E. I. Du Pont De Nemours And Company Substituted phenyltriazolopyrimidine herbicides
JPH0688999B2 (ja) 1988-10-13 1994-11-09 ポーラ化成工業株式会社 ピロロ〔３，２―ｅ〕ピラゾロ〔１，５―ａ〕ピリミジン誘導体およびこれを含有する医薬
CA1330079C (en) 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
JPH085790B2 (ja) 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
WO1990011966A1 (en) * 1989-04-04 1990-10-18 Frederica Catharina Newman Equestrian training aid and method for using the same
DE3942355A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel
DE3942356A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh Verwendung von 1-arylsemicarbaziden zur stabilisierung von enzymsubstraten, entsprechende verfahren und diagnostisches mittel enthaltend einen solchen stabilisator
DE3942357A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
CA2060138A1 (en) 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist
JP3295149B2 (ja) 1991-12-26 2002-06-24 ポーラ化成工業株式会社 ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
JPH05271338A (ja) 1992-03-27 1993-10-19 Nippon Zeon Co Ltd 二置換ジフェニルアセチレン系重合体
EP0649425B1 (en) * 1992-06-17 1999-03-10 PHARMACIA & UPJOHN COMPANY Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
EP0674631B1 (en) 1992-12-17 1999-12-08 Pfizer Inc. Substituted pyrazoles as crf antagonists
BR9307659A (pt) 1992-12-17 1999-06-29 Pfizer Pirazóis e pirazolopirimidinas tendo atividade antagonista crf
FR2701708B1 (fr) 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
DE4311460A1 (de) * 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
FR2714059B1 (fr) 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
CA2192820C (en) 1994-06-16 2000-11-28 Yuhpyng L. Chen Pyrazolo and pyrrolopyridines
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
DK0778277T3 (da) 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
US6664261B2 (en) * 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6255310B1 (en) 1996-02-07 2001-07-03 Neurocrine Biosciences Inc. Thiophenopyrimidines
ES2168237T3 (es) 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
US20010007867A1 (en) * 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
JPH10218881A (ja) * 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
JPH1143434A (ja) 1997-05-30 1999-02-16 Pola Chem Ind Inc カリウムチャンネル開口薬
KR20010014431A (ko) 1997-07-03 2001-02-26 블레어 큐. 퍼거슨 신경 질환 치료용 이미다조피리미딘 및 이미다조피리딘
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
AU2298599A (en) 1998-02-04 1999-08-23 Nissan Chemical Industries Ltd. Pyridine derivatives fused with azole and herbicide
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
DE19948434A1 (de) * 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
SI1218383T1 (sl) * 1999-10-08 2009-04-30 Gruenenthal Chemie Biciklični imidazo-5-il-aminski derivati
CZ300315B6 (cs) * 1999-10-08 2009-04-15 Grünenthal GmbH Na šesticlenném kruhu substituované bicyklické deriváty imidazo-3-yl-aminu, zpusob jejich výroby, jejich použití a léciva tyto látky obsahující
SE9903760D0 (sv) * 1999-10-18 1999-10-18 Astra Ab New compounds
NZ518439A (en) * 1999-10-08 2003-10-31 Gruenenthal Chemie Bicyclic imidazo-3-yl-amine derivatives
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
JP2003516992A (ja) 1999-12-17 2003-05-20 デュポン ファーマシューティカルズ カンパニー イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP3617433B2 (ja) 2000-09-05 2005-02-02 株式会社デンソー 駆動回路
KR20040034594A (ko) 2001-01-26 2004-04-28 브리스톨-마이어스스퀴브컴파니 코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DK2275395T3 (en) * 2001-04-24 2017-02-20 Massachusetts Inst Of Tech (Mit) Copper-catalyzed provision of carbon-carbon compounds.
CA2443802C (en) 2001-04-27 2010-04-13 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
DE60214427T2 (de) 2001-12-19 2007-04-26 Flexitral Inc. Verbesserte geruchsstoffe
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
EP1485384A1 (en) 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
AU2002315614A1 (en) 2002-07-01 2004-01-19 Ognjen Amidzic Method for drawing up data which can be used to assess cognitive or sensomotor capabilities or capacities of people subjected to a test
JP2004053678A (ja) 2002-07-16 2004-02-19 Toyobo Co Ltd Ｉｒアブレーション用積層体
AU2003275589B2 (en) * 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
US20070129382A1 (en) * 2004-02-13 2007-06-07 Dimitri Grigoriadis Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses
JP4832743B2 (ja) 2004-03-29 2011-12-07 ケンブリッジユニバーシティテクニカルサービスリミテッド 化合物の合成方法および合成反応触媒
JP4520215B2 (ja) 2004-04-30 2010-08-04 日油株式会社 分子量が制御された置換ジフェニルアセチレン重合体の製造方法
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
RS52561B (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. COMPOUND 3-PHENYLPYRAZOLO [5,1-B] THIAZOL
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
JP2010235929A (ja) 2009-03-09 2010-10-21 Sumitomo Chemical Co Ltd 重合体
TWI358017B (en) 2009-12-17 2012-02-11 Askey Computer Corp Electronic device loading base

Also Published As

Publication number Publication date
CN102007133A (zh) 2011-04-06
SI2266990T1 (sl) 2013-01-31
AU2009237050A1 (en) 2009-10-22
CN102007133B (zh) 2013-06-12
RS52561B (en) 2013-04-30
IL208393A0 (en) 2010-12-30
AR071655A1 (es) 2010-07-07
UA101836C2 (en) 2013-05-13
HK1151797A1 (en) 2012-02-10
EP2266990A1 (en) 2010-12-29
EP2266990A4 (en) 2011-08-03
KR101601994B1 (ko) 2016-03-17
US8431603B2 (en) 2013-04-30
MY152687A (en) 2014-10-31
TW201004964A (en) 2010-02-01
HRP20121021T1 (hr) 2013-01-31
KR20110002007A (ko) 2011-01-06
PL2266990T3 (pl) 2013-03-29
PE20091890A1 (es) 2009-12-20
EP2266990B1 (en) 2012-09-26
IL208393A (en) 2013-08-29
WO2009128383A1 (ja) 2009-10-22
DK2266990T3 (da) 2013-01-07
MX2010011089A (es) 2010-11-05
CY1113484T1 (el) 2016-06-22
HK1150310A1 (en) 2011-11-25
RU2010146240A (ru) 2012-05-20
CA2721670A1 (en) 2009-10-22
NZ588376A (en) 2011-06-30
US20090259049A1 (en) 2009-10-15
RU2482120C2 (ru) 2013-05-20
CA2721670C (en) 2013-09-10
BRPI0911659B1 (pt) 2020-08-25
ES2396126T3 (es) 2013-02-19
ZA201006764B (en) 2012-03-28
AU2009237050B2 (en) 2013-04-11
JP4654325B2 (ja) 2011-03-16
CL2009000896A1 (es) 2010-04-16
PT2266990E (pt) 2012-12-27
JPWO2009128383A1 (ja) 2011-08-04
BRPI0911659A2 (pt) 2015-10-13

Similar Documents

Publication Publication Date Title
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
BRPI0911659B8 (pt) composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
CR9421A (es) Compuestos heterociclicos fusionados
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
DK2074120T3 (da) Tropan-forbindelser
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
GT200500272A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
EA200900635A1 (ru) Антагонисты прогестеронового рецептора
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
SV2011003944A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexano de ccr2
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
BRPI0620985B8 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
SI1891952T1 (sl) Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
BR112013003752A2 (pt) compostos de tetra-hidrofuranila dissubstituídos como antagonistas do receptor de bradiquinina b1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.